genedrive plc (AIM:GDR)
| Market Cap | 19.67M +125.8% |
| Revenue (ttm) | 1.17M +91.5% |
| Net Income | -5.34M |
| EPS | -0.01 |
| Shares Out | 1.61B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,547,130 |
| Open | 1.212 |
| Previous Close | 1.225 |
| Day's Range | 1.150 - 1.300 |
| 52-Week Range | 0.190 - 1.875 |
| Beta | 0.92 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 2, 2026 |
About genedrive
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet... [Read more]
Financial Performance
In fiscal year 2025, genedrive's revenue was 954,000, an increase of 90.42% compared to the previous year's 501,000. Losses were -5.23 million, -26.06% less than in 2024.
Financial StatementsNews
UK Stock Market News: HSBC, Genedrive, Wizz Air
HSBC Q1 numbers miss, shares down almost 5% in Hong Kong, NHS Trust adopts Genedrive tech, Wizz traffic figures jump
genedrive Quarterly report: H1 2026
genedrive has published its H1 2026 quarterly earnings report on March 30, 2026.
AIM Market Roundup: Trellus Health, Genedrive, Mycelx
Trellus Health, Genedrive, Mycelx are today's top risers, while CPP, PetroTal take the biggest fall on London's AIM market
genedrive Earnings Call Transcript: H2 2025
Rapid pharmacogenetic tests for emergency care are gaining traction, with FY25 revenue reaching GBP 1 million and strong clinical adoption in the U.K. and abroad. Regulatory progress, pilot programs, and new funding position the company for further growth, though additional capital is needed.
genedrive Annual report: H2 2025
genedrive has published its H2 2025 annual report on December 5, 2025.
genedrive Slides: H2 2025
genedrive has posted slides in relation to its H2 2025 quarterly earnings report, which was published on December 5, 2025.
AIM Market Roundup: Genedrive, Idox, Diales
Genedrive, Idox, Diales are today's top risers, while Future Metals, Team take the biggest fall on London's AIM market
AIM Market Roundup: Proteome Sciences, TAP Global, Various Eateries
Proteome Sciences, TAP Global, Various Eateries are today's top risers, while Arc Minerals, Genedrive take the biggest fall on London's AIM
AIM Market Roundup: Genedrive, Petro Matad, Alien Metals
ABC are today's biggest risers and fallers on London's AIM market
AIM Market Roundup: Future Metals, Renalytix, Nativo Resources
Future Metals, Renalytix, Nativo Resources are today's top risers, while genedrive, Rentguarantor take the biggest fall on London's AIM
AIM Market Roundup: 80 Mile, TAP Global, Genedrive
80 Mile, TAP Global, Genedrive are today's top risers, while Active Energy, Finseta take the biggest fall on London's AIM market
AIM Market Roundup: Ethernity, Touchstone, Caledonian Holdings
Ethernity, Touchstone, Caledonian Holdings are today's top risers, while Metals One, Genedrive take the biggest fall on London's AIM market
genedrive Earnings release: Trading Update
genedrive released its earnings on August 11, 2025, summarizing the period's financial results.
Small Cap Stocks: Genedrive, Tern, Conroy Gold
Genedrive, Tern, Mobile Tornado, Conroy Gold, Nativo Resources are today's biggest Small Cap stock movers